Details of Disease

Disease Name

Acquired generalized lipodystrophy

Lawrence-Seip syndrome; acquired lipoatrophic diabetes; Lawrence syndrome; acquired generalized lipodystrophy

Definition

Acquired generalized lipodystrophy belongs to a group of lipodystrophic syndromes characterized by loss of adipose tissue, and is a syndrome of insulin resistance that leads to increased cardiovascular risk. Acquired generalized lipodystrophy is related to a selective loss of subcutaneous adipose tissue occurring exclusively at the extremities (face, legs, arms, palms and sometimes soles).

Disease Hierarchy

DISIZ4RU: Acquired lipodystrophy

DISC6HI8: Generalized lipodystrophy

DISHR0EB: Acquired generalized lipodystrophy

Disease Identifiers

MONDO ID

MONDO_0019193

UMLS CUI

C0271693

MedGen ID

543499

Orphanet ID

79086

SNOMED CT ID

86907008

General Information of Disease (ID: DISHR0EB)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Metreleptin	DM1NOEK	Approved	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PLIN1	TTIV27N	Limited	Biomarker	[2]
------------------------------------------------------------------------------------

References

1	Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016 Dec;45(4):783-797.
2	Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy.Front Immunol. 2018 Sep 19;9:2142. doi: 10.3389/fimmu.2018.02142. eCollection 2018.